Types of lymphoma and method for prognosis thereof
0 Assignments
0 Petitions
Accused Products
Abstract
A method for determining the prognosis of a CD5+DLBCL patient and a CD5-DLBCL patient is provided. It is determined that, in the chromosomal DNA from a patient with lymphoma, (1) the prognosis of the CD5+DLBCL patient with amplification of 13q21.1-q31.3 region is poor; (2) the prognosis of the CD5+DLBCL patient with deletion of 1p36.21-p36.13 region is poor; and (3) the prognosis of the CD5-DLBCL patient with amplification of 5p15.33-p14.2 region is good.
4 Citations
39 Claims
-
1-20. -20. (canceled)
-
21. A method for determining a prognosis of a human patient with diffuse large B-cell lymphoma, the method comprising:
-
isolating chromosomal DNA from a patient with diffuse large B-cell lymphoma; performing microarray analysis to determine whether said isolated chromosomal DNA exhibits at least one of the following members selected from the group consisting of; (1) amplification of an entire chromosomal region 13q21.1-13q31.3; (2) deletion of an entire chromosomal region 1p36.21-p36.13; and (3) amplification of an entire chromosomal region 5p15.33-p14.2; wherein; (a) a poor prognosis is given to a patient with CD5-expressed diffuse large B-cell lymphoma (CD5+ DLBCL) who has amplification of the entire chromosomal region 13q21.1-13q31.3; (b) a poor prognosis is given to a patient with CD5-expressed diffuse large B-cell lymphoma (CD5+ DLBCL) who has deletion of the entire chromosomal region 1p36.21-p36.13; (c) a good prognosis is given to a patient with diffuse large B-cell lymphoma lacking CD5 expression (CD5-DLBCL) who has amplification of the entire chromosomal region 5p15.33-p14.2. - View Dependent Claims (22, 23, 24, 25, 26)
-
-
27. A method for determining a prognosis of a human patient with diffuse large B-cell lymphoma comprising:
-
isolating a biological sample from a patient with diffuse large B-cell lymphoma; and determining whether the biological sample exhibits at least one of the following members selected from the group consisting of; (1) increased expression of at least one gene found in the chromosomal region 13q21.1-13q31.3; (2) decreased expression of at least one gene found in the chromosomal region 1p36.21-p36.13; and (3) increased expression of at least one gene found in the chromosomal region 5p15.33-p14.2; wherein; (a) a poor prognosis is given to a patient with CD5-expressed diffuse large B-cell lymphoma (CD5+ DLBCL) who has increased expression of at least one gene found in chromosomal region 13q21.1-13q31.3; (b) a poor prognosis is given to a patient with CD5-expressed diffuse large B-cell lymphoma (CD5+ DLBCL) who has decreased expression of at least one gene found in chromosomal region 1p36.21-p36.13; (c) a good prognosis is given to a patient with diffuse large B-cell lymphoma lacking CD5 expression (CD5−
DLBCL) who has increased expression of at least one gene found in chromosomal region 5p15.33-p14.2. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36)
-
-
37. An antibody that recognizes the amino acid sequences of SEQ ID NO:
- 4 and SEQ ID NO;
5.
- 4 and SEQ ID NO;
-
38. A purified polynucleotide of the C13orf25 gene having one or more functions selected from the group consisting of:
-
(a) encoding a protein containing the amino acid sequences of SEQ ID NO;
4 and SEQ ID NO;
5; and(b) transcribing precursor micro RNAs miR91-precursor-13 micro RNA, miR18-precursor-13 micro RNA, miR19a-precursor-13 micro RNA, miR19b-precursor-13 micro RNA, and miR92-precursor-13 micro RNA, and transcribing mature micro RNAs miR-17, miR-91, miR-18, miR-19a, miR-20, miR-19b and miR-92.
-
-
39. An oligonucleotide probe comprising a nucleotide sequence that encodes the amino acid sequence set forth in SEQ ID NO:
- 4 or SEQ ID NO;
5, wherein the probe hybridizes to a C13orf25 gene under stringent conditions.
- 4 or SEQ ID NO;
Specification